Oflomil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oflomil

What is Oflomil? - Identity and Classification

To provide quick context, Oflomil is a prescription-only antimicrobial agent used to treat bacterial infections.

Property Description
Active ingredient Ofloxacin
Form Tablet (Oral), Solution (Ophthalmic, Otic)
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose Treatment of Bacterial Infections
Origin Synthetic

Oflomil: Definition and Pharmacological Classification

Oflomil is a medicine containing the active substance Ofloxacin, which is a second-generation fluoroquinolone antibiotic. This places Ofloxacin within a chemically distinct group of synthetic antimicrobial agents. Ofloxacin is indicated for treating a range of susceptible infections, meaning the medicine is designed to combat diverse bacterial pathogens. This pharmacological class is effective against both Gram-negative and Gram-positive organisms.

The brand Oflomil is available in specific markets as an oral tablet and as specialized ophthalmic and otic solutions. This variety in formulation allows for different treatment approaches, providing options for both systemic and localized administration.


Composition, Forms, and General Therapeutic Purpose

The core composition of Oflomil is the single agent Ofloxacin. However, the brand name is sometimes applied to fixed-dose combinations that include other anti-infective agents, such as Ornidazole, to broaden the drug's spectrum. Oflomil is supplied in various dosage forms to target the site of infection effectively. These include the oral tablet for systemic use and sterile solutions for localized topical application in the eye and ear.

Ofloxacin is classified as an anti-infective for systemic and topical use. Its overarching general purpose is to halt and resolve bacterial infections by delivering a bactericidal compound directly to the affected area or system.

Regulatory References

  1. Ofloxacin - StatPearls - NCBI Bookshelf
  2. Fluoroquinolone and quinolone antibiotics: PRAC recommends new restrictions on use | EMA

What side effects are possible with Oflomil?

Oflomil: Possible Side Effects and Safety Information

Oflomil (ofloxacin) is associated with safety warnings typical of the fluoroquinolone class of antibiotics, including the risk of serious adverse reactions impacting the musculoskeletal and nervous systems. Official governmental regulatory warnings highlight the potential for severe, life-threatening events.


Serious and Clinically Significant Adverse Reactions

  • Tendinitis and Tendon Rupture: A documented risk in all age groups, which is significantly increased in patients over 60, those with pre-existing joint/tendon disorders (e.g., rheumatoid arthritis), or when concurrently taking corticosteroid drugs.
  • Myasthenia Gravis Exacerbation: Oflomil may worsen muscle weakness in individuals with myasthenia gravis, potentially leading to severe respiratory compromise and death.
  • Hypersensitivity: Severe allergic reactions (including anaphylaxis) to ofloxacin or other quinolone antibiotics are a contraindication.
  • Nervous System Effects: The drug is associated with central nervous system effects such as dizziness, confusion, seizures, sleeplessness, anxiety, and QT interval prolongation, necessitating caution in patients with a history of epilepsy or heart disease.

Common Adverse Reactions

Commonly reported systemic adverse events affect the gastrointestinal system, including diarrhea, nausea, and stomach pain. For topical formulations (drops/lacquers), common effects are typically localized, such as application site irritation, burning, itching, or transient blurred vision.

Contraindications and Restrictions

Oflomil is contraindicated in patients with a known hypersensitivity to any quinolone/fluoroquinolone antibiotic. Use is also restricted in patients with severe kidney or heart diseases, including irregular heartbeat. Due to the risk of phototoxicity, patients must avoid direct exposure to sunlight or tanning beds during treatment. Concurrent use of certain products, such as caffeine-containing beverages, may increase central nervous system-related side effects like nervousness and sleeplessness.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory information regarding Oflomil (Ofloxacin) overdose highlights specific systemic toxicity and mandatory emergency actions. Documented overdose presentations include central nervous system (CNS) manifestations such as Convulsions, Toxic Psychosis, and Increased Intracranial Pressure (including Pseudotumor Cerebri).

Severe or life-threatening outcomes officially associated with the drug include Aortic Aneurysm and Dissection and the cardiac arrhythmia known as Torsades de Pointes. Due to these risks, Close Monitoring of vital signs and continuous ECG Monitoring are officially required procedures for supportive management. Elderly Patients are noted in official documents to have a population-specific increased risk for severe aortic events.

Health authorities mandate that individuals Seek Emergency Medical Attention immediately for any suspected overdose. Specifically, for the sudden onset of acute dyspnoea, new heart palpitations, or abdominal, chest, or back pain, patients are required to Immediately Consult a Physician in an Emergency Department. The established management approach is limited to Symptomatic Treatment and Supportive Measures, as regulatory documents explicitly state that No specific antidote is known.

Therapeutic Uses of Oflomil

What Oflomil Treats: Main Uses and Benefits

Oflomil (Ofloxacin) is used to provide supportive therapeutic assistance across a range of bacterial infections. It is used for managing the proliferation of susceptible bacteria and supports the relief of associated symptoms. Assisting the patient during difficult episodes by easing distress, it contributes to improved day-to-day comfort. It is applied across domains where additional symptomatic support is needed, and is relevant when short-term symptomatic assistance is appropriate.


Key Therapeutic Applications

Oflomil may be relevant in clinical settings that involve acute or unstable symptom patterns, including infections of the genitourinary tract (such as complicated UTIs and chronic bacterial prostatitis), lower airways (like bacterial pneumonia and chronic bronchitis exacerbations), and various localized infections affecting the skin, eye, and ear. It helps address symptom clusters that may become intense or disruptive, helping patients cope more steadily with symptom fluctuations.

“It is commonly used across conditions presenting with acute episodes where short-term symptomatic assistance is needed.”

Quick Fact: Relief for Functional Distress Oflomil is relevant for easing symptoms linked to organ-specific functional stress, such as dysuria (painful urination) and pelvic discomfort, which interfere with daily stability.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Oflomil? (Ofloxacin)

The official regulatory labeling for Oflomil strictly defines the populations eligible for treatment. Eligibility is determined by age, physiological state, and specific pre-existing health conditions.


Contraindications: Populations Who Must Not Use Oflomil

Use of Oflomil is absolutely prohibited (contraindicated) in the following groups:

  • Patients with known hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotic.
  • Pregnant women and breastfeeding women.
  • Children and growing adolescents (systemic use is strictly contraindicated).
  • Individuals with a history of epilepsy or other central nervous system (CNS) disorders that lower the seizure threshold.
  • Individuals with a history of tendon disorders related to previous fluoroquinolone use.

Restricted and Conditional Eligibility

Use is generally restricted or requires caution for patients with impaired renal function or severe hepatic dysfunction.

  • Organ Function: Patients with kidney or severe liver problems may be eligible, but their use is conditional, often requiring specific functional assessment.
  • Age Groups: Adults are eligible for use. While systemic use is prohibited in adolescents, specific topical (otic) formulations may be approved for use in pediatric patients aged six months and older. Older adults are at increased risk for tendon and aortic issues, requiring greater caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oflomil (Ofloxacin) exhibits officially documented interaction patterns that affect both its systemic exposure and its pharmacodynamic effects with co-administered substances. The regulatory profile outlines specific restrictions and timing requirements necessary to avoid clinically significant outcomes.

Co-administration with cation-containing products such as aluminum or magnesium antacids, iron salts, zinc preparations, Sucralfate, or Didanosine (chewable/buffered) significantly reduces Oflomil's oral absorption. To prevent this reduction in exposure, these products must be administered at least 2 hours before or 2 hours after Oflomil oral tablets. Similarly, high-calcium foods and drinks may decrease drug absorption.

In terms of drug–drug interactions, Oflomil carries a caution regarding the lowering of the cerebral seizure threshold when taken concurrently with Theophylline or certain Non-Steroidal Anti-inflammatory Drugs (NSAIDs). Use with medicines known to prolong the QTc interval may increase the risk of cardiac arrhythmias and is often restricted or contraindicated in labeling. Furthermore, Oflomil may potentiate the effects of Vitamin K Antagonists (e.g., Warfarin), requiring coagulation monitoring. The clearance of Oflomil is reduced by drugs that inhibit renal tubular secretion, such as Probenecid, leading to increased systemic exposure. The combination with systemic corticosteroids increases the documented risk of tendon disorders.

Mechanism of Action

How Oflomil Works

The mechanism of Oflomil involves a dual action focused on disrupting core microbial cellular processes.


Targeted Inhibition of Bacterial DNA Replication

The active component, Ofloxacin, operates by directly engaging and inhibiting two essential bacterial enzymes: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. Ofloxacin stabilizes the transient complexes formed between these enzymes and the bacterial DNA, thereby physically blocking the necessary process of DNA repair and separation required for replication and transcription. This molecular interference triggers an overwhelming cascade of irreparable double-strand DNA breaks, resulting in the rapid bactericidal (cell-killing) physiological effect on the pathogen population.


Complementary Cytotoxicity and Synergy

In combination products, the second agent, Ornidazole, extends the mechanism by targeting anaerobic bacteria and protozoa through a distinct pathway. Once inside these organisms, it is chemically activated, generating highly reactive free radicals that directly fragment the microbial DNA helix. This additive, cytotoxic action is complementary to Ofloxacin's mechanism, resulting in a broader range of microbial cellular destruction, encompassing both aerobic and anaerobic microorganisms.


Mechanistic Constraints of Resistance

The action of Oflomil is biologically constrained when bacteria develop Efflux Pumps or acquire Chromosomal Mutations in the target enzyme genes. These limitations prevent the drug from binding effectively or reaching the necessary high intracellular concentration, resulting in a reduction of the full bactericidal cascade and a constrained microbial cytotoxic effect.

Dosage and Administration Information

Administration Guidelines for Oflomil (Amorolfine)

Oflomil, which contains the active ingredient Amorolfine, is a topical antifungal medicine. The instructions for its use are established for the topical application of the lacquer formulation.

Administration Instructions

Usage Attribute Guideline (Amorolfine 5% Lacquer)
Route of Administration Topical (application directly onto the affected nail)
Dosing Schedule Apply once or twice weekly
Preparation Requirements Before each application, affected areas must be cleaned and filed. Use the provided files to remove as much of the infected nail as possible, and cleanse the surface using the provided cleansing pad.
Procedural Steps 1. File the affected nail surface. 2. Cleanse the nail with the pad. 3. Apply the lacquer over the entire surface of the infected nail. 4. Allow the product to dry completely (approximately 3 minutes).
Missed-Dose Rules If an application is missed, apply the medicine as soon as possible, then resume the original schedule.
Special Conditions Before re-applying, old lacquer must be removed using the provided cleansing pad, and the nail filed again. Avoid contact with eyes, ears, and mucous membranes.

These instructions define the standardized approach to using the medicine. The regimen establishes a specific, recurring topical application frequency, which is necessary for proper adherence to the labeling. The preparation steps—filing and cleansing—are required to ensure that the active ingredient can properly treat the affected area before each new application.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oflomil

Oflomil (Ofloxacin) has been evaluated in various clinical research settings to understand its profile in settings involving bacterial infections. The evidence used to support its formal indications is mainly derived from controlled clinical trials, including Randomized Controlled Trials (RCTs), and systematic reviews that compile data across multiple studies. Research describes the patterns observed when the agent was studied for specific outcomes, where researchers evaluated outcomes such as documented pathogen eradication and symptom evolution.


Evidence for Urinary and Prostatic Infections

Research has examined the use of this compound in settings involving complicated conditions characterized by fluctuating or episodic manifestations in the urinary tract, including complicated UTIs and acute pyelonephritis, and in long-term bacterial issues like chronic bacterial prostatitis.

The evidence base for these uses is rooted in comparative studies and RCTs where the agent was evaluated in adult patient populations. Researchers designed these studies to monitor the documentation of microbiological eradication (the documentation of pathogen absence) and Clinical Success Rates (the documentation of symptom evolution patterns). Systematic analyses describe patterns observed in the studies regarding pathogen documentation when compared to other agents studied in the trials.

What remains uncertain: Evidence quality varies across studies, particularly older ones, which may make contemporary comparisons challenging. Furthermore, regulatory and scientific bodies have noted that antimicrobial resistance is a growing global concern, and this factor may affect the applicability of past study findings to current patient scenarios.

Research on Pathogen Clearance and Symptom Documentation

This research specifically focused on episodes where symptoms become more noticeable, such as when outcomes related to physical discomfort like painful urination (dysuria) was studied for change over the observation course. For chronic conditions, research examined how frequently the infection recurred after the treatment period was completed, monitoring the observed patterns regarding infection recurrence.


Evidence for Respiratory and Localized Ocular Infections

This part of the evidence was studied for its application in systemic respiratory issues and highly localized surface infections. For hospitalized patients with Community-Acquired Pneumonia (CAP), the evidence consists of Randomized Controlled Trials (RCTs). For the ophthalmic solution, the research base is characterized by rigorous, double-masked clinical trials where the compound was evaluated in patients with bacterial conjunctivitis.

Documented Outcomes for Acute Infections

In CAP trials, research examined the Clinical Success Rates when compared to established standard-of-care antibiotic regimens. Studies also monitored measures of resource utilization, such as the required length of intravenous therapy. For ocular infections, studies explored outcomes related to inflammatory or irritative states, such as time to documentation of resolution of redness and discharge, alongside Microbiological Eradication Rate. The findings describe group patterns, not personal outcomes, and research provides insight into short-term changes for both respiratory and ocular conditions.

Key Studies & References

  1. National Institutes of Health (NIH) - StatPearls: Ofloxacin Overview and Therapeutic Use
  2. NICE Guideline: Acute conjunctivitis

Frequently Asked Questions (FAQ)

Common questions about Oflomil (FAQ)


Q: What are the most common side effects of Oflomil reported in official documents?

Official product information describes the most common reported systemic side effects as gastrointestinal issues, including nausea, diarrhea, and stomach pain. When Oflomil is used as an eye or ear drop, the most frequently reported effects are generally localized, such as burning or irritation at the application site.


Q: Is it true that Oflomil can impact liver function?

Regulatory documents state that signs of a serious liver problem, such as jaundice (yellowing of the skin or eyes), can occur as a rare but serious adverse reaction. If changes like these are observed, it is described as a sign that medication use may need to be assessed immediately.


Q: Can Oflomil affect my mood or mental state?

Official product information indicates that Oflomil can be associated with effects on the central nervous system (CNS). These effects have included reported cases of anxiety, confusion, dizziness, and sleeplessness.


Q: Do herbal or vitamin supplements affect how Oflomil works?

Regulatory documents advise that Oflomil’s oral absorption may be reduced by products containing cations, such as iron, zinc, or calcium. These elements are often present in multivitamins and some mineral supplements. Regulatory guidance indicates the time should be separated to avoid this interaction.


Q: How long does it typically take for Oflomil to start having an effect?

According to regulatory documents, the drug starts to be absorbed into the body immediately after administration. Maximum concentrations of Oflomil in the bloodstream are typically reached one to two hours following the oral dose, indicating when the drug is most active systemically.


Q: Is it normal to not feel the effects of Oflomil immediately?

It is a general expectation that the effects of Oflomil are not felt immediately. The time needed for the medicine to reach its maximum concentration and begin its bactericidal action means that patients typically do not experience instant relief upon taking the pill.


Q: How long can a person continue to use Oflomil according to studies?

The duration of Oflomil use is defined by the specific infection being treated and the patient's condition. Treatment courses, as specified in official prescribing information, can range from a few days to several weeks.


Q: What should I know about stopping Oflomil?

Regulatory information strongly emphasizes that the full, prescribed course of treatment should be completed entirely. Stopping Oflomil early, even if symptoms improve, is generally described as discouraged in official documents, unless a healthcare professional instructs otherwise.


Q: Can I take Oflomil for just a few days?

The necessity of completing the full course means that use for only a few days is typically not described in official guidance, unless the specific prescribing information for your condition indicates a very short duration.


Q: Can I drink alcohol if I am using Oflomil?

Regulatory documentation notes that Oflomil can cause central nervous system (CNS) effects like dizziness and confusion. These effects may be potentially heightened when combined with other CNS depressants, which includes alcoholic beverages.


Q: What happens when Oflomil is mixed with caffeine?

Official documentation indicates that concurrent use of Oflomil with caffeine-containing beverages may increase central nervous system-related side effects. Patients have reported increased nervousness and sleeplessness when this combination is used.


Q: Are there any foods or drinks that should be avoided with Oflomil?

Regulatory documents state that Oflomil’s oral absorption can be significantly reduced by cation-containing products (such as iron or magnesium antacids) and high-calcium foods and drinks like dairy products. To minimize this effect, regulatory documents describe that these items require separation from Oflomil oral administration by at least two hours.


Q: What kind of common drug interactions are described for Oflomil?

Official product information describes several categories of drug interactions. These include medicines that reduce Oflomil's absorption, drugs that lower the seizure threshold (like some NSAIDs or Theophylline), medicines that affect heart rhythm (QTc prolonging agents), and agents that potentiate the effects of blood thinners.


Q: Is Oflomil suitable for people with kidney/heart conditions?

The official labeling states that use of Oflomil is restricted or requires caution for individuals with severe kidney or heart diseases, including those with irregular heartbeats. For patients with impaired renal function (kidney problems), official information indicates that a specific functional assessment may be required.


Q: Why is Oflomil usage sometimes restricted for people with certain health issues?

Usage of Oflomil is restricted in certain populations due to the documented potential for serious adverse reactions typical of its drug class. These concerns include an increased risk of tendon damage, worsening of muscle weakness in conditions like Myasthenia Gravis, and specific effects on the central nervous and cardiac systems.


Q: What happens if I miss taking a dose of Oflomil?

Regulatory guidance for the oral tablet indicates that if a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the regular dosing schedule should be resumed immediately.


Q: Does Oflomil work differently in men compared to women?

According to pharmacokinetic studies described in official documents, the drug’s absorption rate into the body is generally unaffected by gender. This suggests the biological availability of Oflomil is typically similar for both men and women.

How should Oflomil be stored and disposed of?

Storage and Disposal of Oflomil

Oflomil must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept from freezing and protected from excess heat, moisture, and direct light. Always store Oflomil in its original container and keep the container tightly closed.

Child-Safety and Stability

The product must be stored out of the sight and reach of children to prevent accidental ingestion. Do not keep outdated medicine; adhere to the expiration date printed on the packaging.

Disposal Instructions

To dispose of unused or expired Oflomil, utilize a drug take-back program if one is available in your area. If a take-back program is unavailable, official regulatory guidance advises mixing the medicine with an unappealing substance, sealing it in a container, and disposing of it in the household trash. Oflomil is not on the list of medicines recommended for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oflomil found in:

A-Z Index: